Alain Corbani, head of mining at Montbleu Finance and manager of the Global Gold and Precious Fund, sees the gold price reaching US$5,000 per ounce in the near term.
He sees real interest rates and the US dollar as the key factors to watch, but noted that other elements are also adding tailwinds.
Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.
Discoveries made by companies in the genetics sector help support every other life science industry in a variety of ways.
One of the genetic sector’s major contributions is the discovery of new genetic drivers of diseases. Genetic testing has grown substantially over the last few years, thanks to advances in technology; growth has also been spurred by an increase in chronic diseases and the continuing development of test kits for therapeutic areas with unmet medical needs.
Gene therapy is also a huge driver of growth in the overarching genetics market. This important segment of the life science market is focused on how genes can help treat or prevent serious conditions in patients. This includes the potential for healthcare professionals to implement gene therapy at the cellular level instead of using medication or surgery, replacing ‘faulty’ genes with new ones to potentially cure diseases.
Pharma and biotech companies often dabble in genetics along with their core disciplines, meaning that some firms may also have operations in other areas.
The top NASDAQ genetics stocks listed below have products related to gene therapy, genetic testing, genetically defined cancers and rare genetic diseases.
Data for this list of genetics stocks on the NASDAQ was collected on December 31, 2025, using TradingView’s stock screener, and stocks with market caps above US$50 million were considered.
Year-over-year gain: 143.8 percent
Market cap: US$10.87 billion
Share price: US$72.14
Avidity Bioscience is a biopharma firm developing a new form of RNA therapy called antibody oligonucleotide conjugates (AOC) that target the genes causing rare muscle diseases.
Through its proprietary AOC platform, Avidity developed programs for three rare muscle diseases: AOC 1001 for myotonic dystrophy type 1, AOC 1044 for Duchenne muscular dystrophy and AOC 1020 for facioscapulohumeral muscular dystrophy. The company is also working to expand its pipeline into cardiology and immunology.
In October 2025, Avidity entered into a definitive agreement to be acquired by Novartis (NYSE:NVS), which will include the company’s late-stage neuromuscular programs (AOC 1001, 1020, 1044) and the AOC platform, for US$12 billion.
Avidity’s early-stage precision cardiology programs will spin off into a new public company prior to closing in H1 2026. The spin-off will also have rights to use and develop the AOC platform for cardiology applications.
Year-over-year gain: 36.52 percent
Market cap: US$3.13 billion
Share price: US$17.12
Wave Life Sciences is another clinical-stage firm focused on unlocking insights from human genetics to deliver RNA-based medicines. The company’s PRISM platform is targeting both rare and prevalent disorders. Its pipeline includes clinical programs for Duchenne muscular dystrophy, alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program for WVE-007 in obesity.
Wave Life Sciences advanced its PRISM RNA platform across multiple programs in 2025. It is also performing a Phase 1 trial testing its WVE-007 obesity candidate, which is an investigational INHBE GalNAc-siRNA using Wave’s proprietary SpiNA design.
In December, the company reported positive interim data from the WVE-007 trial, which showed that a single dose resulted in sustained Activin E reduction, supporting infrequent dosing. Target engagement updates and body composition readouts are planned for Q1 2026.
Year-over-year gain: 33.15 percent
Market cap: US$1.47 billion
Share price: US$23.86
UniQure is a gene therapy company focused on patients with severe medical needs. In November 2022, the US Food and Drug Administration (FDA) approved the company’s gene therapy Hemgenix (etranacogene dezaparvovec), which is the world’s first gene therapy for hemophilia B.
Today, uniQure’s proprietary gene therapy pipeline includes treatments for patients with Huntington’s disease, refractory temporal lobe epilepsy, ALS and Fabry disease.
Its gene therapy pipeline advanced in 2025, with positive Phase I/II topline data for Huntington’s disease candidate AMT-130 showing 75 percent slowing of disease progression at three years via cUHDRS, alongside 60 percent functional capacity preservation.
While data from the Phase I/II study led the FDA to grant AMT-130 breakthrough therapy designation in April, in December the agency told UniQure it believes the data may not be adequate to support a pre-biologics license application under the accelerated approval pathway. The company is pursuing a follow-up meeting.
Year-over-year gain: 186.96 percent
Market cap: US$1.81 billion
Share price: US$31.74
Stoke Therapeutics is another biotech company with a focus on developing RNA medicine. With its proprietary research platform TANGO, which stands for targeted augmentation of nuclear gene output, the company is developing antisense oligonucleotides to selectively restore protein levels.
Stoke’s first product candidate, zorevunersen (STK-001), is in clinical testing for the treatment of Dravet syndrome, a severe form of genetic epilepsy. The company is also developing STK-002 for the treatment of autosomal dominant optic atrophy, an inherited optic nerve disorder.
Both candidates advanced in 2025, with STK-001 enrolling patients in Phase 3 after positive long-term data showed seizure reductions and cognitive gains. Likewise, STK-002’s clinical development program is being informed by results, presented in October, of a Phase 1 two year natural history study on the disease progression of autosomal dominant optic atrophy.
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
The copper price climbed to a fresh record on Tuesday (January 6), with persistent supply disruptions and trade uncertainty pushing the metal to a nearly 30 percent rally since October.
Benchmark three month copper on the London Metal Exchange (LME) rose as much as 3.1 percent in early trading to an all‑time high of US$13,387.50 per metric ton before settling slightly lower, but still above US$13,200.
The jump marks another milestone in a rally that first saw copper breach US$12,000 late in December last year.
Copper is widely used across the industrial economy, from construction and power infrastructure to electric vehicles and data centers that support artificial intelligence growth. Analysts attribute the gains to a combination of production setbacks at major mines and heightened concerns that prospective US trade tariffs could further disrupt flows.
Large copper-mining operations such as Freeport-McMoRan’s (NYSE:FCX) Grasberg complex in Indonesia have faced challenges since last year, while a strike at Capstone Copper’s (TSX:CS,ASX:CSC,OTC Pink:CSCCF) Mantoverde mine in Chile has reduced output prospects in one of the world’s top copper‑producing nations.
The threat of new tariffs under the Trump administration has also shaped expectations. Traders have moved to ship refined copper into the US ahead of any potential levies, tightening supply elsewhere. Furthermore, data show copper stocks in Comex warehouses have jumped to more than 450,000 metric tons, well above last year’s levels.
Market watchers expect many of the forces that drove copper through 2025 to persist.
Supply constraints are expected to remain acute this year as aging mines and capacity shortfalls weigh on availability. New projects such as Arizona Sonoran Copper Company’s (TSX:ASCU,OTCQX:ASCUF) Cactus project and the long‑anticipated Resolution mine in the US are still years from significant output.
Copper demand is projected to grow as the global energy transition accelerates.
“A huge amount of this tightness has to do with US tariff concerns,” she said.
China, the world’s largest copper consumer, is also shaping the outlook. Despite weakness in its property sector, the country posted economic growth and is expected to prioritize copper‑intensive sectors under its new five year plan.
Longer‑term projections from industry groups suggest structural demand growth will outpace supply additions.
A UN report estimates that copper demand could rise 40 percent by 2040, requiring substantial investment and new mines just to keep pace. Likewise, Wood Mackenzie forecasts that copper demand will increase 24 percent by 2035, while the International Copper Study Group predicts a refined copper deficit of 150,000 metric tons in 2026 alone.
Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.
E-Power Resources offers investors high-grade exposure to the rapidly expanding flake graphite sector through one of Québec’s most promising districts. With a strategic land position, near-surface discoveries, and a leadership team experienced in exploration and capital markets, E-Power is positioned to help supply North America’s critical battery materials chain.
E-Power Resources (CSE:EPR) is a Montréal-based company focused on advancing its flagship Tetepisca graphite property in Québec’s North Shore region. The company’s mission is to delineate and develop a high-grade, near-surface flake-graphite resource capable of supplying future North American battery-anode demand.
Since entering the Tetepisca district in 2019, E-Power has systematically advanced its project from regional geophysics to mapping, sampling, drilling and metallurgical testing. This disciplined exploration pipeline has confirmed the presence of district-scale, high-purity graphite mineralization within the same geological sequence that hosts neighboring deposits such as Focus Graphite’s Lac Tetepisca and Nouveau Monde Graphite’s Uatnan, which together hold more than 120 million tons (Mt) measured + indicated at approximately 14 percent Cg.
Graphite demand is accelerating globally as electric-vehicle production and energy-storage capacity expand. Québec’s hydroelectric grid, pro-mining policy environment, and rapidly developing anode-manufacturing infrastructure make it a world-class jurisdiction for low-carbon graphite development. Within this setting, E-Power’s land position, grade profile and technical results uniquely position the company to become a core participant in Canada’s graphite-to-battery supply chain.
The Tetepisca graphite property is approximately 220 km north of Baie-Comeau, covering 234 contiguous claims (~12,840 ha) in the heart of the Tetepisca Graphite District (TGD). The property is 100-percent-owned by E-Power and hosts the same graphitic metasedimentary units that define the district’s producing and feasibility-stage assets.
The TGD is an emerging flake-graphite camp that now hosts more than 120 Mt of measured and indicated resources averaging ~14 percent Cg across nearby projects such as Nouveau Monde Graphite’s Uatnan and Focus Graphite’s Lac Tetepisca deposits.
E-Power controls the largest contiguous land position in the district, strategically covering the same graphitic metasedimentary horizons that host these deposits. The district’s proximity to the planned 200,000 tpy graphite-anode facility in Baie-Comeau creates a unique alignment of resource, infrastructure and processing capability, positioning E-Power as a potential key upstream feed source for Québec’s integrated graphite-to-anode supply chain.
E-Power’s work since 2021 has validated the property’s high-grade, near-surface potential.
E-Power’s 2025–2026 work program will focus on advancing the Tetepisca property toward an initial resource estimate. Key activities include expanded fieldwork and metallurgical testing at the Graphi-Centre, Captain Cosmos and Syndicate showings; follow-up ground and drone-borne geophysical surveys to refine drill targets; and a focused drilling campaign designed to define near-surface, high-grade graphite zones. In parallel, the company is initiating early environmental baseline and access studies to support future development and potential partnerships within Québec’s growing graphite-to-anode supply chain.
Jean-Michel Gauthier contributes significant expertise in capital markets, corporate development and strategic positioning within the resource sector. His focus will be on ensuring the optimal deployment of capital and maximizing the inherent value of the Tetepisca Project as it advances through key de-risking stages.
Mark Billings is a highly respected finance professional in the Canadian resource sector, bringing extensive investment banking and corporate finance experience. His prior roles, including VP corporate finance at Desjardins Securities, provide a crucial foundation for guiding E-Power’s capital formation and strategic financing plans necessary for the Tetepisca Project’s development phases.
Jamie Lavigne is a professional economic geologist with over 30 years of experience in exploration and mine development. He has worked with major Canadian and Australian mining companies and several junior explorers and operates his own consulting firm. Lavigne holds a B.Sc. from Memorial University and an MSc. from the University of Ottawa. He is a member of L’Ordre des Géologues du Québec and the Northwest Territories and Nunavut Association of Professional Engineers and Geoscientists.
Paul Haber brings over 20 years of experience in corporate finance and capital markets. He has served as CFO, board member, and audit chair for numerous public and private companies, including XTM (CSE:PAID), South American Silver (TSX:SAC), and Migao Corporation (TSX:MGO). A CPA and CA, Haber began his career at Coopers & Lybrand and holds an Honours B.A. in Management from the University of Toronto. He also holds a Chartered Director designation from the DeGroote School of Business and the Conference Board of Canada.
Sen. Ted Cruz, R-Texas, on Wednesday called on Congress during a Senate hearing to impeach two federal judges, making his most elaborate case yet for imposing the extraordinary sanction on a pair of closely scrutinized jurists.
Cruz acknowledged that impeaching federal judges is exceedingly rare — 15 have been impeached in history, typically for straightforward crimes like bribery — but the Texas Republican argued it was warranted for judges James Boasberg and Deborah Boardman.
‘Rarer still, until now, were the deeper offenses the framers feared most — judges who, without necessarily breaking a criminal statute, violate the public trust, subvert the constitutional order or wield their office in ways that injure society itself,’ Cruz said. ‘That is why, throughout history, Congress recognized that impeachable misconduct need not be criminal.’
Cruz, a Senate Judiciary Committee member with an extensive legal background, said the House needed to initiate impeachment proceedings over controversial gag orders Boasberg signed in 2023 and a sentence Boardman handed down last year in the case of Justice Brett Kavanaugh’s attempted assassin.
Impeachment proceedings must be initiated in the House and typically run through the House Judiciary Committee.
Russell Dye, a spokesman for the GOP-led committee, said ‘everything is on the table’ when asked if Chairman Jim Jordan, R-Ohio, was open to the idea. If the House were to vote in favor of impeachment, it would then advance to the Senate. Two-thirds of senators would need to vote to convict the judges and remove them, a highly improbable scenario because the vote would require some support from Democrats.
Cruz’s counterpart at the hearing, Sen. Sheldon Whitehouse, D-R.I., defended the judges and accused Republicans of threatening impeachment as an effort to intimidate the judiciary because it routinely issues adverse rulings against the Trump administration.
‘There was a time when I’d have hoped a Senate Judiciary subcommittee would not be roped into a scheme to amplify pressure and threats against a sitting federal judge,’ Whitehouse said. ‘But here we are.’
In the case of Boardman, a Biden appointee, the judge sentenced Sophie Roske, who previously went by Nicholas Roske, to eight years in prison after the Department of Justice sought a 30-year sentence. Roske pleaded guilty to attempting to murder Kavanaugh. Boardman said she factored into her sentence that Roske identified as transgender and therefore faced unique adversity.
Cruz argued Democrats’ concerns about threats that judges have faced for ruling against President Donald Trump fell on deaf ears, in his view, because they did not speak out about Boardman’s leniency toward Roske.
‘My Democrat colleagues on this committee do not get to give great speeches about how opposed they are to violence against the judiciary, and, at the same time, cheer on a judge saying, ‘Well, if you attempt to murder a Supreme Court justice, and you happen to be transgender, not a problem. We’re going to deviate downward by more than two decades,” Cruz said.
In the case of Boasberg, former special counsel Jack Smith subpoenaed several Republican Congress members’ phone records while conducting an investigation into the 2020 election and Trump’s role in the Jan. 6 Capitol riot. Smith sought gag orders so that the senators would not immediately be notified about the subpoenas, and Boasberg authorized those orders.
Prosecutors seeking gag orders is not unusual, but senators have layers of protection from prosecution under the Constitution. The targeted Republicans have decried the subpoenas, saying their rights were violated.
Smith and an official representing the federal courts have both said that Boasberg was not notified that the subpoenas and gag orders were related to members of Congress.
Rob Luther, a law professor at George Mason University, was a witness for Republicans at the hearing and said Boasberg still should not have signed the gag orders without knowing who they applied to. Luther cited stipulations included in the orders.
‘One must ask on what basis Judge Boasberg found that the disclosure of subpoenas would result in destruction of or tampering with evidence, intimidation of potential witnesses, and cause serious jeopardy to the investigation, end quote,’ Luther said. ‘Did Judge Boasberg merely rubber stamp the requested gag order, or was he willfully blind?’
Smith’s actions also aligned with a DOJ policy at the time that did not require the special counsel to alert the court that the subpoenas targeted senators, a point raised by Sen. John Kennedy, R-La., during the hearing. Luther said the policy did not matter.
‘DOJ policy does not supplant federal law,’ he said.
Sen. Lindsey Graham announced Wednesday that President Donald Trump has approved a Russian sanctions bill designed to pressure Moscow to end its war with Ukraine.
Graham revealed the development in a post on X, describing it as a pivotal shift in the U.S. approach to the Russia-Ukraine conflict.
‘After a very productive meeting today with President Trump on a variety of issues, he greenlit the bipartisan Russia sanctions bill that I have been working on for months with Senator Blumenthal and many others,’ Graham said.
‘This will be well-timed, as Ukraine is making concessions for peace and Putin is all talk, continuing to kill the innocent.’
According to the Sanctioning Russia Act of 2025, the bipartisan legislation is designed to grant Trump sweeping, almost unprecedented, authority to economically isolate Russia and penalize major global economies that continue to trade with Moscow and finance its war against Ukraine.
Most notably, the bill would require the United States to impose a 500% tariff on all goods imported from any country that continues to purchase Russian oil, petroleum products or uranium. The measure would effectively squeeze Russia financially while deterring foreign governments from undermining U.S. sanctions.
‘This bill will allow President Trump to punish those countries who buy cheap Russian oil fueling Putin’s war machine,’ Graham said.
‘This bill would give President Trump tremendous leverage against countries like China, India and Brazil to incentivize them to stop buying the cheap Russian oil that provides the financing for Putin’s bloodbath against Ukraine.’
Graham said voting could take place as early as next week and that he is looking forward to a strong bipartisan vote.
The move on the Russian sanctions bill follows another sharp escalation in America’s clampdown on Moscow. Earlier Wednesday, U.S. forces reportedly seized an oil tanker attempting to transport sanctioned Venezuelan oil to Russia.
Graham publicly celebrated the seizure in another post on X, describing it as part of a broader winning streak of U.S. intervention aimed at Venezuela and Cuba.
In the post, he also took aim at critics such as Sen. Rand Paul, who has opposed the bill, arguing that it would damage America’s trade relations with much of the world.
Fox News Digital reached out to the White House for comment.
Former Vice President Al Gore on Wednesday condemned President Donald Trump’s move to withdraw the U.S. from United Nations-linked climate initiatives.
Gore claimed in a post on X that ‘the most significant challenge of our lifetimes’ is ‘the climate crisis.’
‘The ongoing work of the IPCC, UNFCCC, and other global institutions remains essential to safeguarding humanity’s future,’ he asserted, referring to the Intergovernmental Panel on Climate Change (IPCC), the United Nations Framework Convention on Climate Change (UNFCC).
‘By withdrawing from the IPCC, UNFCCC, and the other vital international partnerships, the Trump Administration is undoing decades of hard-won diplomacy, attempting to undermine climate science, and sowing distrust around the world,’ he wrote.
Trump issued a memorandum ordering U.S. withdrawal from the two initiatives that Gore mentioned as well as scads of other entities.
The president’s memorandum lists the Intergovernmental Panel on Climate Change under a grouping of ‘Non-United Nations Organizations.’ But the website ipcc.ch states, ‘The Intergovernmental Panel on Climate Change (IPCC) is the United Nations body for assessing the science related to climate change.’
In the memorandum, the president declared that he has ‘determined that it is contrary to the interests of the United States to remain a member of, participate in, or otherwise provide support to the organizations listed in section 2 of this memorandum.’
Secretary of State Marco Rubio said in a statement, ‘As this list begins to demonstrate, what started as a pragmatic framework of international organizations for peace and cooperation has morphed into a sprawling architecture of global governance, often dominated by progressive ideology and detached from national interests.’
Gore, who served as vice president alongside Democratic President Bill Clinton, lost the 2000 presidential contest to Republican George W. Bush.
The seizure of a Russian-linked oil tanker in the North Atlantic has highlighted ‘worry’ among NATO and Nordic-Baltic governments over dark fleet vessels and the type of crews onboard, according to a maritime intelligence analyst.
U.S. military and Coast Guard personnel boarded the Marinera between Iceland and the U.K. Wednesday as it operated under deceptive shipping practices, including flying a false flag and violating sanctions.
According to Reuters, Russian authorities demanded the humane treatment and repatriation of the crew members.
Windward maritime intelligence analyst Michelle Wiese Bockmann claimed the Marinera’s ownership had just been transferred to Burevestmarin LLC, a Russian company.
‘We do not know the status of these sailors and seafarers, who are Russian nationals,’ Wiese Bockmann told Fox News Digital. ‘That lack of clarity is common with dark fleet tankers.
‘The Marinera did have its ownership transferred to a newly formed Russian company, with the registered owner, ship manager and commercial manager being Burevestmarin LLC.’
She also suggested NATO and the Nordic-Baltic 8+ group of governments have been ‘worried’ about sanctioned oil tankers with unauthorized personnel onboard, including ‘armed guards.’
‘Increasingly, and I know the Nordic Baltic 8+ governments are worried about the fact that you are having unauthorized people also on board, also known as armed guards,’ Wiese Bockmann said. ‘But it is highly irregular.
‘Armed guards are rarely seen and typically used on ships that are transiting the Gulf of Aden or the Red Sea and are therefore assessed as at risk from attack by Houthis or pirates,’ she added.
After the seizure, White House press secretary Karoline Leavitt rejected Russian demands for special treatment of the Marinera’s crew during her regular briefing Wednesday.
‘This was a Venezuelan shadow fleet vessel that had transported sanctioned oil,’ Leavitt said.
‘The vessel was deemed stateless after flying a false flag, and it had a judicial seizure order. And that’s why the crew will be subject to prosecution.’
Russia’s Foreign Ministry said it was ‘closely following’ the situation, according to the state-run TASS news agency.
Wiese Bockmann noted that dark fleet crews are often multinational, typically involving a Russian master with Chinese, Indian or Filipino crew members.
‘There is a blurring of commercial and military shipping around the dark fleet,’ she said. ‘What we’re seeing now is something that has really only emerged in the last six or seven months.’
European authorities have also begun holding crews accountable, particularly when captains are ‘facilitating dangerous deceptive shipping practices, such as spoofing and going dark,’ she explained.
‘The EU recently sanctioned the captain of a tanker who refused orders from the Estonian navy (Jaguar) to be stopped for inspection last May. And the French charged a captain over his refusal to comply with orders and failure to justify a flag’s nationality after authorities intercepted a dark fleet tanker in the Atlantic last October,’ Wiese Bockmann added.
As previously reported by Fox News Digital, a second vessel, the M. Sophia, was also boarded in international waters near the Caribbean while en route to Venezuela.
Fox News Digital has reached out to the White House for comment.
President Donald Trump on Wednesday signed a presidential memorandum directing the U.S. to withdraw from 66 international organizations, ordering executive departments and agencies to cease participation in and funding of entities the administration says no longer serve U.S. interests.
The memorandum follows a State Department review ordered earlier this year under Executive Order 14199 and applies to 35 non-United Nations organizations and 31 United Nations entities, according to the White House.
In the memorandum, Trump said he reviewed Secretary Rubio’s findings and determined it is ‘contrary to the interests of the U.S. to remain a member of, participate in, or otherwise provide support’ to the listed organizations.
The order directs all executive departments and agencies to take immediate steps to effectuate the withdrawals as soon as possible. For United Nations entities, withdrawal means ceasing participation in or funding to the extent permitted by law.
The administration framed the move as part of Trump’s broader ‘America First’ agenda aimed at restoring American sovereignty and ending taxpayer support for organizations it views as wasteful, ineffective or contrary to U.S. interests.
Review of additional international organizations remains ongoing, according to the White House.
Secretary of State Marco Rubio said the withdrawals fulfill a key commitment of Trump’s presidency.
‘Today, President Trump announced the U.S. is leaving 66 anti-American, useless, or wasteful international organizations,’ Rubio said in a post on X. ‘Review of additional international organizations remains ongoing.’
Rubio said the administration concluded the institutions were ‘redundant in their scope, mismanaged, unnecessary, wasteful, poorly run, captured by the interests of actors advancing their own agendas contrary to our own, or a threat to our nation’s sovereignty, freedoms, and general prosperity.’
‘It is no longer acceptable to be sending these institutions the blood, sweat, and treasure of the American people, with little to nothing to show for it,’ Rubio said. ‘The days of billions of dollars in taxpayer money flowing to foreign interests at the expense of our people are over.’
The list includes organizations involved in areas such as climate, energy, development, governance, migration and gender policy, according to the White House. The White House published the full list alongside the order.
Rubio said the withdrawals reflect a shift in how the administration views international engagement.
‘We will not continue expending resources, diplomatic capital, and the legitimizing weight of our participation in institutions that are irrelevant to or in conflict with our interests,’ Rubio said. ‘We seek cooperation where it serves our people and will stand firm where it does not.’
The White House and the State Department did not immediately respond to Fox News Digital’s request for comment.
The growing prevalence of chronic diseases like cancer and diabetes is driving increasing innovation in medical device technology. In 2024 alone, 30 new devices were approved by the US Food and Drug Administration (FDA).
Wearable medical devices and the use of artificial intelligence in medical technology are two key trends in this sector.
Investors who want exposure to this wave of growth may want to consider NASDAQ small-cap medical device stocks. Below is a list of the top NASDAQ medical device companies based on year-on-year gains.
All data was compiled on December 31, 2025, using TradingView’s stock screener, and the medical device makers listed below had market caps between US$50 million and US$500 million at that time.
Year-on-year gain: 50.86 percent
Market cap: US$173.24 million
Share price: US$3.50
MDxHealth is a commercial-stage precision diagnostics company specializing in molecular tests for urologic cancers, particularly prostate cancer, using genomic, epigenetic and exosomal technologies. Its US headquarters and operations are located in Irvine, California.
The company offers non-invasive and tissue-based diagnostic assays that run on standard PCR platforms.
In September, MDxHealth acquired Exosome Diagnostics from Bio-Techne (NASDAQ:TECH) for US$15 million, adding the ExoDx Prostate urine test to its portfolio. The deal also includes a CLIA-certified clinical laboratory and related assets. The deal is expected to generate over US$20 million in revenue in 2026.
Year-on-year gain: 50.13 percent
Market cap: US$269.6 million
Share price: US$5.82
KORU Medical Systems develops and manufactures medical devices and supplies in the US and internationally, with a focus on mechanical infusion products. Its Freedom Syringe Infusion System first received FDA clearance in 1994.
Based on this system, its primary products include the Freedom60 and FreedomEdge syringe infusion systems, Precision Flow Rate Tubing and High-Flo Subcutaneous Safety Needle Sets.
KORU Medical Systems submitted a 510(k) premarket notification to the FDA on December 30, 2025, seeking clearance for its FreedomEdge system to deliver Phesgo — a HER2+ breast cancer targeted biologic — subcutaneously, targeting infusion centers to cut chair time and boost efficiency.
The company stated this is part of its strategy to expand the indications of FreedomEdge to the wider oncology infusion center market.
Year-on-year gain: 1.71 percent
Market cap: US$86.81 million
Share price: US$1.19
Vivani Medical is a clinical-stage biopharmaceutical company developing miniature, long-term subdermal drug implants using its proprietary NanoPortal technology to treat chronic conditions like obesity and type 2 diabetes.
Headquartered in Alameda, California, Vivani focuses on GLP-1 implants that provide steady drug release over six months to improve adherence and tolerability compared to daily pills or weekly injections.
In August, Vivani Medical reported positive Phase 1 results from its LIBERATE-1 trial of the NPM-115 exenatide implant, confirming safety and steady drug release for obesity treatment without major side effects.
The company plans to rapidly advance its NPM-139 semaglutide implant after it achieved preclinical results of sustained 20 percent weight loss. It is planning a Phase 1 clinical study in the first half of 2026.
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.